Table 1.
Demographic and clinical characteristics
| Characteristic | No. (%) of Patients |
|---|---|
| Sex | |
| Male | 52 (63) |
| Female | 31 (37) |
| Age, years | |
| Median 62 y (25–80 y) | |
| <50 | 13 (16) |
| ≥50 | 70 (84) |
| NE | |
| Pathological | 38 (46) |
| Normal | 45 (54) |
| KPS | |
| <70% | 12 (14) |
| ≥70% | 71 (86) |
| Epilepsy | |
| Yes | 34 (41) |
| Not | 49 (59) |
| GBM sitea | |
| Frontal lobe | 18 (22) |
| Fronto-temporal lobe | 7 (8) |
| Temporal-occipital lobe | 3 (4) |
| Fronto-parietal lobe | 6 (7) |
| Temporal lobe | 24 (29) |
| Temporo-parietal lobe | 7 (8) |
| Parietal lobe | 7 (8) |
| Parieto-occipital lobe | 4 (5) |
| Corpo callosum, talamic | 3 (4) |
| Multifocal | 4 (5) |
| Extent of surgery | |
| Residual >20% | 29 (35) |
| Residual <20% | 5 (6) |
| Total | 49 (59) |
| RPA Class | |
| III | 3 (4) |
| IV | 47 (57) |
| V | 18 (22) |
| VI | 15 (17) |
| Stupp Protocol | |
| Yes | 47 (57) |
| No/Palliative care | 36 (43) |
| MGMT | |
| Methylated | 14 (36) |
| Unmethylated | 30 (17) |
| Not available | 39 (47) |
Abbreviations: GBM, glioblastoma multiforme; KPS, Karnofsky performance status; MGMT, O6-methylguanine- methyltransferase enzyme; NE, neurological examination; RPA, Recursive Partitioning Analysis.
aCorrelation between GBM localization and epilepsy at the χ2 test, P .021.